Related Experiment Videos
Psoriatic arthritis treatment: biological response modifiers
1Seattle Rheumatology Associates, 1101 Madison St, 10th floor, Seattle, WA 98104, USA. pmease@nwlink.com
Annals of the Rheumatic Diseases
|February 15, 2005
Summary
Targeted biological therapies, like tumor necrosis factor (TNF) blockers, show significant success in treating psoriatic arthritis (PsA). These treatments improve joint health, skin lesions, and overall function, offering a safe and effective option for chronic inflammatory disorders.
Area of Science:
- Immunology
- Rheumatology
- Dermatology
Background:
- Chronic inflammatory disorders share overlapping immunopathology.
- Targeted biological therapies offer new treatment avenues.
- Psoriatic arthritis (PsA) involves joint, skin, and entheseal inflammation.
Purpose of the Study:
- To review the efficacy and safety of targeted biological therapies in psoriatic arthritis (PsA).
- To highlight the role of tumor necrosis factor (TNF) blockers in managing PsA.
- To discuss potential future therapeutic targets and combination strategies.
Main Methods:
- Review of clinical trial data for PsA treatments.
- Analysis of the impact of TNF blockers on various PsA domains.
- Discussion of emerging biological agents and combination therapies.
Main Results:
- Tumor necrosis factor (TNF) blockers (etanercept, infliximab, adalimumab) demonstrated significant clinical benefits in PsA.
- These agents improved joint symptoms, skin lesions, enthesitis, and dactylitis.
- Therapy with TNF blockers was generally safe and well-tolerated in clinical trials.
Conclusions:
- Targeted biological therapies, particularly TNF blockers, are effective for psoriatic arthritis (PsA).
- These treatments address multiple facets of PsA, including skin and joint manifestations.
- Further research into other targeted agents and combination therapies is warranted.